key: cord-0816594-e6we5try authors: Brill, Livnat; Rechtman, Ariel; Shifrin, Alla; Rozenberg, Ayal; Afanasiev, Svetlana; Zveik, Omri; Haham, Nitzan; Levin, Neta; Vaknin-Dembinsky, Adi title: Longitudinal humoral response in MS patients treated with Cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine date: 2022-05-10 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2022.103863 sha: 78e15a2f328221345e04e56538c91d9a6ae91f0c doc_id: 816594 cord_uid: e6we5try BACKGROUND: Multiple sclerosis (MS) patients receive immunomodulatory treatments which can influence their ability to maintain vaccine specific serological response overtime. MS patients treated with Cladribine tablets developed a positive serology response following two doses of mRNA COVID-19 vaccine. However, there is only limited data regarding the effect of cladribine tablets on long-term humoral response after the second and the third booster. METHODS: Serology response to SARS-CoV-2 was tested in healthy controls (HCs) and MS patients treated with cladribine tablets 6 and 9-12 months after the second dose, and 1 and 3-6 months following the third booster-dose of the BTN162b2 mRNA vaccine. RESULTS: Thirty-five out of 36 MS patients treated with cladribine tablets and 100% (46/46) of HCs had a positive serology response up to 10 months after the second vaccine dose. In addition, all cladribine tablets -treated MS patients (22/22) and HCs (24/24) had a positive robust serology response following the third vaccine with a positive humoral response sustain up to 6 months. One month after the third vaccine dose IgG levels were significantly lower in patients treated with cladribine tablets compared to HCs (15598+11313 vs 26394+11335, p<0.01). Six-month post second vaccine and 3-6 months post third vaccine there was no difference in IgG levels between the groups (1088.0±1072.0 vs 1153.0±997.1, p=0.79; 5234+4097 vs 11198+14679, p=0.4). CONCLUSION AND RELEVANCE: MS patients treated with cladribine tablets have sustained positive vaccine specific serology response following the second and third SARS-CoV-2 vaccine dose. The resurgence of corona virus disease worldwide despite the fact that high percentages of the population have been vaccinated with two doses of mRNA vaccine, along with increase data of waning vaccine immunity of the mRNA vaccines over time, has led to the recommendation of a third vaccine dose 1,2 . The third dose of mRNA vaccines has been shown to elicit a strong humoral response [3] [4] [5] . COVID-19 vaccines have been reported to be safe for multiple sclerosis (MS) patients, with no evidence of increased risk of relapse [6] [7] [8] . Patients with MS are treated with various diseasemodifying treatments (DMTs) that affect different levels of the immune system and may affect the humoral immune response to COVID-19 vaccines 9 . Cladribine tablets (Mavenclad), a purine analogue selectively target lymphocytes and causes marked reduction of B cells and a modest reduction in T and NK cells 10-12 . We and others have shown that MS patients treated with cladribine tablets develop a humoral response to two doses of the mRNA SARS-CoV-2 vaccines 13-15 . However, only a few studies have examined the effect of cladribine tablets on a long-term humoral response after the second vaccination and data on the response following the third booster vaccine dose is limited 16 . In the current work, we present a study assessing the serology response of MS patients treated with cladribine tablets, 6 and 9-12 months after the second vaccine dose as well as following the third vaccine dose. The Hadassah and Rambam Medical Organization Ethics Committees approved this study. All patients provided written informed consent (975-20-HMO, 0188-21-RMB). Patients with MS treated with cladribine tablets who received two or three doses of COVID-19 mRNA vaccine (BTN162b2 Pfizer/BioNTech) were included. None of the patients were infected with COVID-19 until 30.11.2021 (Before the omicron variant outbreak in Israel). Patients who were pregnant, breastfeeding, or diagnosed with another autoimmune disease were excluded from the study. The study cohort include 44 MS patients treated with cladribine tablets (Female:Male = 33:11, average age 39.45±12.88 years, EDSS 2.88±1.98, average disease duration 8.24±7.44 years, and lymphocytes count 1.35±0.86) and forty-six HCs. Thirty-six patients with MS treated with cladribine tablets and 46 HCs provided blood samples 6 months following the second vaccine dose, 5 cladribine tablets treated MS patients gave blood 9-12 months following the second vaccine. Blood samples were analyzed 1 month following the third vaccine in 17 cladribine treated MS patients and 24 HCs, and from 5 cladribine tablets treated patients and 8 HCs, 3-6 months following the third vaccine dose. Enrolled patients provided a blood sample 6 and/or 9-12 months after the second COVID-19 mRNA vaccine, and 1 and 3-6 months after the third vaccine. Serology response to SARS-CoV-2 Spike Receptor Binding Domain (RBD) was measured using the Architect SARS-CoV-2 IgG II Quant assay (Abbott Diagnostics). A positive response was defined by an IgG titer of ≥50 arbitrary units (AU/ml). The Kolmogorov-Smirnov test was used to assess the distribution of all parameters considered in this study. A student t-test was performed to measure differences in serology response between the HCs and MS patients treated with cladribine tablets. Correlations between demographic and clinical variables and serology response were assessed by Pearson's correlation. Differences were considered significant when P <.05. In order to find the long-term vaccine specific serology response in MS patients treated with cladribine tablets we analyzed blood samples 6 and 9-12 months following the second vaccine dose. This study follows our recent report on serology responses 2-3 weeks following second vaccine in patients treated with cladribine tablets 14 No correlation was found between SARS-CoV-2 IgG levels 6 months following the second vaccine and lymphocytes count (r=0.03, p=0.86), EDSS (r=-0.11, p=0.51), age (r=-0.03, p=0.88), disease duration (r=-0.15, p=0.4), and the time between last cladribine dose and vaccination (r=0.15, p=0.49). In addition, no difference was found between patients who received one or two courses of cladribine tablets prior to vaccination (835 ±825.5 vs 1275 ±1285, p=0.4). A national third-dose vaccination campaign was initiated in Israel on August 1, 2021. To date, a third vaccine is recommended in many countries. Several groups have demonstrated a reduction in the odds of SARS-CoV-2 infection and hospitalization within a few weeks of receiving the third vaccine compared with receiving the 2 primary doses 3, 17, 18 . According to a number of studies, serology response of healthy individuals following the third vaccine is greater compared to the second vaccine booster 4,5 . In the current study, we describe longitudinal serology response in MS patients treated with cladribine tablets at 6 and 9-12 months after the second dose as well as at 1 and 3-6 months after the third dose of the BNT162b2 mRNA vaccine. Our results show that 97% of MS patients treated with cladribine tablets have a positive serology response following 6 months and up to 12 months after the second dose. In addition, in all participants, the third vaccine results in a robust increased serological response; however, the average response in MS patients treated with cladribine tablets is lower than that of HCs. We did not find a correlation between IgG levels and age, EDSS, lymphocytes count, disease duration, and duration between last cladribine dose and vaccination. Also, no difference was found between patients who received one or two courses of cladribine tablets before the third vaccine dose. To date, several reports show that the majority of MS patients treated with cladribine tablets have positive serology response after receiving two doses of the mRNA vaccine. Nevertheless, it is still unclear whether IgG levels are comparable to HCs [13] [14] [15] 19, 20 . The protection of the mRNA vaccines against COVID-19 fades after several months 1,2 . Goldberg et al., showed that the risk for infection was significantly higher for participants that were vaccinated 6 months before the study, compared to those who were vaccinated later 2 . This parallels the known decrease in IgG levels 6 months following a second vaccination and infection [21] [22] [23] . In addition, 5-6 months following the second vaccine there is a significant overall decrease at memory B-cells and neutralizing antibodies, however T cell responses are preserved 24 . Of note is that it is still unclear what is cutoff IgG level that would provide protection against infection or from severe COVID-19 disease course 25 . In addition, the cross-sectional natures of the vaccine response studies to date do not reach consensus about the best timing of vaccines and effects of boosters or third doses to maximize humoral and cellular responses 26 . Data on the long-term durability of the serology response of MS patients treated with cladribine tablets is scarce. We found that up to 12 months following the second and up to 6 months after the third vaccine dose, both HCs and MS patients treated with cladribine tablets have a positive serology response. The humoral response of patients treated with cladribine tablets was significantly lower 1 month following the third vaccine dose but not 6 months post second vaccine dose and 3-6 months after the third vaccination. Timing of the vaccine is known to affect humoral response 27 . While all HCs were vaccinated with the third dose 5-6 months after the second dose, in the group of MS patients treated with cladribine tablets there was a wider range between the two doses. Patients that were vaccinated with the third dose more than 7 month after the second, had lower IgG titers in average. Further, larger MS cohort studies may provide insight on the cause of the difference between HCs and cladribine tablets treated patients. In conclusion, we found that MS patients treated with cladribine tablets have sustained positive vaccine specific serology response following the second and third vaccine dose of the BNT162b2 mRNA vaccine. Correlation of SARS-CoV-2-breakthrough infections to time-fromvaccine Waning Immunity after the BNT162b2 Vaccine in Israel Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years COVID-19 vaccination in patients with multiple sclerosis : What we have learnt by COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After Vaccination Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis Humoral-and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron Relationship between Antibody Levels and SARS-Cov-2 Reinfection Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice Evaluation of COVID-19 vaccination strategies with a delayed second dose Vaknin-Dembinsky has served on scientific advisory boards for F. Hoffmann-La Roche, Biogen, Sanofi-Aventis and the healthcare business of Merck KGaA, Darmstadt, Germany and has received grants from F. Hoffmann-La Roche, Biogen and the healthcare business of Merck KGaA